Delanzomib
Delanzomib (CEP-18770) is a potent and orally active chymotrypsin-like activity of the proteasome inhibitor with an IC50 of 3.8 nM. Delanzomib inhibits NF-κB activity, induces cancer cell apoptotic, and has strong antiangiogenic and anti-cancer activities[1].
Product Specifications
CAS Number
[847499-27-8]
Product Name Alternative
CEP-18770
UNSPSC
12352005
Hazard Statement
H302, H312, H332
Target
Apoptosis; NF-κB; Proteasome
Type
Reference compound
Related Pathways
Apoptosis; Metabolic Enzyme/Protease; NF-κB
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Delanzomib.html
Purity
98.0
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC(C)C[C@@H](B(O)O)NC([C@@H](NC(C1=NC(C2=CC=CC=C2)=CC=C1)=O)[C@H](O)C)=O
Molecular Formula
C21H28BN3O5
Molecular Weight
413.28
Precautions
H302, H312, H332
References & Citations
[1]Glinsukon T, et al. Acute toxicity of capsaicin in several animal species[J]. Toxicon, 1980, 18 (2) : 215-220.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
SARS-CoV-2 B.1.618 Spike S1+S2 trimer Protein (ECD, His tag)(HPLC-verified)
SARS-CoV-2 B.1.618 Spike S1+S2 trimer Protein (ECD, His tag)(HPLC-verified)